Scope
NICE NG111 covers antibiotic treatment and safety-netting for acute pyelonephritis across adults, pregnancy and childhood. This selected summary emphasizes cultures, severity assessment, prompt review and distinct prescribing populations. Its drug choices reflect the UK guidance and require adaptation to current local susceptibility and prescribing information.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm the infection and obtain cultures
- Obtain urine before antibiotics in acute pyelonephritis and send it for culture and susceptibility testing. In people aged 16 years and over, use a midstream sample; in younger children follow the paediatric UTI collection pathway. [1]
- Offer antibiotics, selecting treatment by severity, previous cultures and antibiotic exposure. Structural or functional urinary-tract abnormality and immunosuppression increase complication risk. [1]
- Review the antibiotic when culture results arrive. If the organism is resistant, change according to susceptibility, using a narrow-spectrum antibiotic wherever possible. [1]
Recognize deterioration and arrange appropriate care
- Refer people aged 16 years and over to hospital when symptoms or signs suggest sepsis or another serious illness. Consider referral or specialist advice for pregnancy, significant dehydration, inability to take oral fluids or medicines, or increased complication risk. [1]
- Reassess if symptoms worsen at any time or fail to begin improving within 48 hours of antibiotics. Reconsider alternative diagnoses, sepsis and resistance related to previous antibiotic use. [1]
- Explain diarrhoea and nausea as antibiotic adverse effects, but also that nausea with vomiting can signal worsening pyelonephritis. Advise urgent reassessment for deterioration, systemic illness or no initial improvement within 48 hours. [1]
Choose route and review promptly
- Use oral antibiotics first when the patient can take them and illness severity does not require intravenous treatment. Review intravenous antibiotics by 48 hours and consider oral step-down whenever possible. [1]
- Antibiotic selection must account for local resistance and the separate adult, pregnancy and paediatric tables. The NICE options are UK prescribing guidance; susceptibility results and the local antimicrobial policy remain central. [1]
- For pain, advise paracetamol and sufficient fluid intake to avoid dehydration. These measures accompany assessment and antibiotic treatment. [1]
Selected oral choices for non-pregnant adults
- For non-pregnant women and men aged 16 years and over, NICE lists oral cefalexin 500 mg twice or three times daily for 7–10 days; severe infection has different higher-dose options and needs severity-based assessment. [1]
- In non-pregnant people aged 16 years and over, oral co-amoxiclav is an option only when culture confirms susceptibility: 500/125 mg three times daily for 7–10 days. Do not treat this culture-dependent option as unrestricted empirical therapy. [1]
- For non-pregnant people aged 16 years and over, culture-susceptible infection can be treated with trimethoprim 200 mg twice daily for 14 days under this table. [1]
- Reserve ciprofloxacin for non-pregnant people aged 16 years and over when other first-choice antibiotics are unsuitable; the oral table specifies 500 mg twice daily for 7 days. Discuss its potentially disabling, prolonged or irreversible adverse effects. [1]
Keep pregnancy and childhood pathways separate
- For pregnant patients aged 12 years and over, NICE lists cefalexin as the first oral option and cefuroxime as the first intravenous option when vomiting, unable to take oral therapy or severely unwell. Seek microbiology advice for alternatives or combinations where resistance or sepsis is a concern. [1]
- Children under 3 months need paediatric specialist referral and intravenous antibiotics following the fever-under-five pathway. For older children, use the paediatric UTI referral pathway and age- and size-appropriate antibiotic prescribing. [1]
- If a child develops pyelonephritis while receiving antibiotic prophylaxis, treat with a different antibiotic rather than increasing the prophylactic drug’s dose. For children initially treated intravenously, review by 48 hours and consider oral step-down for a total 10-day course. [1]
Limitations and use
- This is not a complete sepsis, obstructed-urinary-tract or source-control pathway. Severe illness and structural disease require appropriate urgent specialist assessment.
- Only selected adult oral regimens are reproduced. Paediatric doses, complete intravenous schedules and renal or hepatic adjustments require the full table and current product guidance. Pregnancy and paediatric regimens must not be extrapolated from the adult table.
- UK antibiotic preferences do not establish Indian empirical susceptibility or local availability. Culture results, allergies, interactions and current regional resistance must inform prescribing.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Pyelonephritis (acute): antimicrobial prescribing
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 31 October 2018
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.